The question begins with what remains
Treatment can change a tumour substantially whilst leaving malignant cells behind. Those cells may differ in their biology and in the ways they respond to further treatment. The surrounding environment can also influence what happens next. [M05]
A survivor is a starting observation
Finding a cell after treatment tells us that it survived under those conditions. It does not, on its own, establish whether that cell rebuilds the tumour, supports another population, or eventually stops contributing.
NEUVIOR’s selected research question connects the identity of survivors with their contribution to regrowth. The aim is to test whether changing a particular population changes what the remaining disease can do.
Why the timing of a study matters
An intervention can reduce cell numbers immediately without changing longer-term regrowth. Following the system after an intervention ends helps distinguish a temporary effect from a more durable change in its behaviour.
That distinction is central to the Glioblastoma Recurrence Programme. It guides the choice of models, comparisons, and outcomes before a candidate is advanced.